Earnings
Cambridge, Massachusetts-based Epizyme emphasized its efforts to move tazemetostat back into clinical trials in its second-quarter financial report.
Regeneron Pharmaceuticals reported its second-quarter financial results, citing quarterly total revenues of $1.608 billion, up 9 percent from the same quarter in 2017 of $1.470 billion.
As its acquisition by Takeda Pharmaceutical edges closer and closer, Shire reported a solid second-quarter.
For its second-quarter financial report, Paris-based Sanofi reported a decrease in net sales for the quarter of 5.7 percent, down to 8.176 billion euros. Sanofi’s diabetes and cardiovascular franchises have struggled in the U.S.
Pfizer reported its second-quarter financials, with adjusted earnings per share coming in at $0.81, exceeding the consensus forecast of $0.74, up 20.9 percent from the same period in 2017.
Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.
Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by Eliquis (apixaban) and Opdivo (nivolumab).
Despite what has been described as a series of missteps in the last year, Celgene’s second-quarter financial report was promising.
Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of the year and a 20 percent increase in its core earnings per share (EPS).
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.
PRESS RELEASES